Poxel

Regulatory Filings • Oct 20, 2025

Availability of a first document in response to questions received from shareholders

LYON, France, October 20, 2025

POXEL SA (Euronext: POXEL - FR0012432516), informs that a first document in response to the questions received from the shareholders is available in French on the Company's website, in the "Investors" section, "Shareholder Info", "Documentation".

This first document covers the main themes raised by shareholders over the past few months, concerning:

• the strategy of partnerships established in the past,
• the current relationships of Poxel with Merck Serono,
• the business partnership with Sumitomo for TWYMEEG® in Japan, and
• the rights related to Roivant.

The publication of this document is part of the new governance's desire to strengthen communication with all its shareholders and establish a constructive dialogue with them.

About Poxel

Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunctionassociated steatohepatitis (MASH) and rare disorders. For the treatment of MASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

For more information, please visit: www.poxelpharma.com

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or

performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is otherwise not responsible for the content of external hyperlinks referred to in this press release.

Contacts - Investor Relations / Media

NewCap Aurélie Manavarere, Théo Martin / Arthur Rouillé investors@poxelpharma.com +33 1 44 71 94 94